Read by QxMD icon Read

Schizophrenia and negative symptoms

Xu Li, Zhi Li, Ke Li, Ya-Wei Zeng, Hai-Song Shi, Wen-Lan Xie, Zhuo-Ya Yang, Simon S Y Lui, Eric F C Cheung, Ada W S Leung, Raymond C K Chan
Anhedonia, the diminished ability to experience pleasure, is a challenging negative symptom in patients with schizophrenia and can be observed in at-risk individuals with schizotypy. Deficits in hedonic processing have been postulated to be related to decreased motivation to engage in potentially rewarding events. It remains unclear whether non-pharmacological interventions, such as cognitive training, could improve anhedonia. The present study aimed to examine the neural mechanism for alleviating hedonic deficits with working memory (WM) training in individuals with social anhedonia...
October 18, 2016: Scientific Reports
Takeshi Shimada, Ai Nishi, Tomotaka Yoshida, Sachie Tanaka, Masayoshi Kobayashi
We described an individualized occupational therapy (IOT) programme and examined the effects of adding IOT to group OT (GOT) on improving neurocognition, symptoms and social functioning among recently hospitalized patients with schizophrenia. The Brief Assessment of Cognition in Schizophrenia-Japanese version (BACS-J), the Positive and Negative Syndrome Scale (PANSS) and the Global Assessment of Functioning scale were used for outcome evaluations. Fifty-one patients were voluntarily assigned to either the GOT + IOT (n = 30) or GOT alone (n = 21) groups based on their preferences...
October 17, 2016: Occupational Therapy International
Yu-Xi Wang, Ping Zhang, Li-Min Xin, Lin Chen, Yan-Hong Liu, Yun-Ai Su, Tian-Mei Si
This study was designed to examine the validity and reliability of the Chinese version of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia taking antipsychotics. It was conducted in a sample of 135 patients aged between 18 and 50 years old and diagnosed with schizophrenia. Demographic data and clinical features were assessed with PRSexDQ, the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression (CGI), and the Udvalg for Kliniske Undersøgelser (UKU) Side Effects Rating Scale...
September 30, 2016: Psychiatry Research
Pedro Shiozawa, July Silveira Gomes, Daniella Valverde Ducos, Henrique Teruo Akiba, Álvaro Machado Dias, Alisson Paulino Trevizol, Ricardo R Uchida, Natasza Orlov, Quirino Cordeiro
Introduction: We report a transcranial direct current stimulation (tDCS) protocol over the dorsolateral prefrontal cortex (DLPFC) combined with cognitive training in schizophrenia. Method: We assessed psychotic symptoms in nine patients using the Positive and Negative Syndrome Scale (PANSS). All evaluations were scored at baseline, at the end of the intervention protocol, and during a 4-week follow-up. The tDCS protocol consisted of 10 consecutive sessions over 5-day periods...
July 2016: Trends in Psychiatry and Psychotherapy
Dea Seidenfaden, Ulla Knorr, Mia Greisen Soendergaard, Henrik Enghusen Poulsen, Anders Fink-Jensen, Martin Balslev Jorgensen, Anders Jorgensen
BACKGROUND: Childhood adversity is a well-established risk factor for the development of schizophrenia. In particular, there is evidence that childhood adversity increases the occurrence of positive symptoms, possibly through glucocorticoid influences on dopaminergic neurotransmission. AIMS: To compare levels of childhood trauma in schizophrenia patients vs. healthy control persons, and to study the association between childhood adversity and the symptomatology of adulthood schizophrenia, as well as subjective and biological markers of psychological stress...
September 24, 2016: Comprehensive Psychiatry
Ana M Sánchez-Torres, M Rosa Elosúa, Ruth Lorente-Omeñaca, Lucía Moreno-Izco, Victor Peralta, Manuel J Cuesta
Psychopathological symptoms and cognitive impairment are related to psychosocial functioning. However, the nature of the association of cognitive impairment with psychosocial functioning still remains under scrutiny. We aimed to examine the relationships of premorbid adjustment, lifetime psychopathological dimensions, and cognitive performance with the typical level of psychosocial functioning during the previous year. We assessed ninety patients with schizophrenia spectrum disorders and affective disorders with psychotic symptoms to collect data on premorbid adjustment, lifetime psychopathological dimensions, cognitive performance and psychosocial functioning...
October 9, 2016: Schizophrenia Research
Christoph U Correll, Leslie Citrome, Peter M Haddad, John Lauriello, Mark Olfson, Stephen M Calloway, John M Kane
Long-acting injectable antipsychotics (LAIs) are among the most effective treatments in psychiatry, yet they remain underutilized in clinical practice. Although LAIs are typically used to maintain treatment adherence in patients with chronic schizophrenia, recent research has suggested that they may also provide an effective treatment strategy for patients with early-phase or first-episode disease. In October 2015, a group of 8 experts on the management of schizophrenia and LAIs met to evaluate the evidence surrounding the efficacy, safety, and cost-effectiveness of LAIs and to develop practical recommendations regarding the clinical use, education, and unmet needs related to LAIs...
2016: Journal of Clinical Psychiatry
Arka Chattopadhyay, Stephen Frey, Ghiselle Green
BACKGROUND: Bifeprunox is a novel antipsychotic drug designed to treat schizophrenia. However, research into the drug was ceased in 2009 due to rejection of licence to go to market by the US Food and Drug Administration (FDA), who could not approve the drug for acute or long-term symptoms of schizophrenia because more research was required to demonstrate convincing effects "beyond those already achieved" with currently licenced drugs. There were also concerns expressed over one death of a person whilst on the drug...
October 12, 2016: Cochrane Database of Systematic Reviews
Seon-Kyeong Jang, Sujin Kim, Chai-Youn Kim, Hyeon-Seung Lee, Kee-Hong Choi
Severe emotional disturbances such as anxiety and depression have been closely related to aberrant attentional processing of emotional stimuli. However, this has been little studied in schizophrenia, which is also characterized by marked emotional impairments such as heightened negative affect and anhedonia. In the current study, we investigated temporal dynamics of motivated attention to emotional stimuli in schizophrenia. For this purpose, we tracked eye movements of 22 individuals with schizophrenia or schizoaffective disorder (ISZs) and 19 healthy controls (HCs) to emotional (i...
October 2016: Journal of Abnormal Psychology
Robin E Gearing, Kathryne B Brewer, Irfan Mian, Kiara Moore, Prudence Fisher, Jane Hamilton, James Mandiberg
AIM: The timely identification and treatment of psychosis are increasingly the focus of early interventions, with research targeting the initial high-risk period in the months following first-episode hospitalization. Ongoing treatment after stabilization is also essential in the years following a first-episode psychosis (FEP), but has received less research attention. In this study, variables that could impact continued psychiatric service utilization by adolescents following their FEP and temporal patterns in service utilization are examined...
October 11, 2016: Early Intervention in Psychiatry
A Hasan, T Wobrock, B Guse, B Langguth, M Landgrebe, P Eichhammer, E Frank, J Cordes, W Wölwer, F Musso, G Winterer, W Gaebel, G Hajak, C Ohmann, P E Verde, M Rietschel, R Ahmed, W G Honer, P Dechent, B Malchow, M F U Castro, D Dwyer, C Cabral, P M Kreuzer, T B Poeppl, T Schneider-Axmann, P Falkai, N Koutsouleris
Impaired neural plasticity may be a core pathophysiological process underlying the symptomatology of schizophrenia. Plasticity-enhancing interventions, including repetitive transcranial magnetic stimulation (rTMS), may improve difficult-to-treat symptoms; however, efficacy in large clinical trials appears limited. The high variability of rTMS-related treatment response may be related to a comparably large variation in the ability to generate plastic neural changes. The aim of the present study was to determine whether negative symptom improvement in schizophrenia patients receiving rTMS to the left dorsolateral prefrontal cortex (DLPFC) was related to rTMS-related brain volume changes...
October 11, 2016: Molecular Psychiatry
Saeed Shoja Shafti, Abbas Azizi Khoei
BACKGROUND: Several lines of evidence suggest that the cholinergic system may be disrupted in schizophrenia and so this may contribute to the cognitive impairments of schizophrenic patients. Because such deficits do not respond to neuroleptic treatment, different approaches have been done by acetylcholinesterase inhibitors (AChEIs). The objective of the present assessment was to evaluate the safety and clinical effects of rivastigmine, as an adjunctive drug, on the clinical symptoms of schizophrenia...
October 2016: Therapeutic Advances in Psychopharmacology
Sibylle Metzler, Diane Dvorsky, Christine Wyss, Carlos Nordt, Susanne Walitza, Karsten Heekeren, Wulf Rössler, Anastasia Theodoridou
An important aim in schizophrenia research is to optimize the prediction of psychosis and to improve strategies for early intervention. The objectives of this study were to explore neurocognitive performance in individuals at risk for psychosis and to optimize predictions through a combination of neurocognitive and psychopathological variables. Information on clinical outcomes after 24 months was available from 118 subjects who had completed an extensive assessment at baseline. Subjects who had converted to psychosis were compared with subjects who had not...
September 30, 2016: Psychiatry Research
Agnieszka Potasiewicz, Małgorzata Hołuj, Tomasz Kos, Piotr Popik, Hugo R Arias, Agnieszka Nikiforuk
The cognitive impairments and negative symptoms experienced by schizophrenia patients still await effective treatment. Alpha7 nicotinic acetylcholine receptors (α7 nAChRs) have gain considerable attention in this regard. It has been recently proposed that positive allosteric modulators (PAMs) of α7 nAChRs may represent an alternative strategy to that based on orthosteric agonists. The aim of the present study is to evaluate the efficacy of PAM-2 (3-furan-2-yl-N-p-tolyl-acrylamide) against cognitive deficits and negative-like symptoms in a rat model of schizophrenia based on administration of ketamine, a NMDAR antagonist...
October 4, 2016: Neuropharmacology
Andrea Murru, Bernardo Carpiniello
The first psychotic episode is classically viewed as a critical period which management is important in determining the long-term outcome of the schizophrenia (SCZ). For this reason, the duration of untreated illness (DUI), defined as the interval between the onset of the psychiatric disorder and the administration of the first pharmacological treatment, is a clinical variable that has been increasingly investigated due to its potentially modifiable nature and its value as a predictor of outcome. DUI is poorly applicable and highly unreliable in psychosis...
October 4, 2016: Neuroscience Letters
Seo-Eun Cho, Kyoung-Sae Na, Seong-Jin Cho, Seung Gul Kang
An increasing amount of evidence indicates that d-serine, a potent and selective endogenous coagonist of the N-methyl-d-aspartate receptor (NMDAR), is efficacious in the treatment of schizophrenia. Although the therapeutic efficacy of d-serine supplementation is based on the d-serine deficit and NMDAR hypofunction hypothesis, it has not been confirmed whether d-serine levels are decreased in patients with schizophrenia compared to healthy controls. We searched the following electronic databases: Embase, Ovid Medline, and the Cochrane Library...
October 4, 2016: Neuroscience Letters
Manli Huang, Yi Huang, Liang Yu, Jianbo Hu, Jinkai Chen, Pingbo Jin, Weijuan Xu, Ning Wei, Shaohua Hu, Hongli Qi, Yi Xu
BACKGROUND: This study aimed to explore differences in links between negative symptoms and neurocognitive deficits in adolescent and adult patients with first-episode schizophrenia. Schizophrenia is a mental disorder often characterized by positive and negative symptoms, reduced emotional expression, excitatory status, and poor cognitive ability. The severity of negative symptoms in patients with schizophrenia was reported to be more related to poor quality of life, weak functional ability, and heavy burden from families than with the severity of positive symptoms...
October 6, 2016: BMC Psychiatry
Joseph M Johnson, Chris Y Wu, Gerald Scott Winder, Michael I Casher, Vincent D Marshall, Jolene R Bostwick
Objective This study examines the association between cannabis use and the hospital course of patients admitted to the psychiatric inpatient unit with a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder. Many confounding variables potentially contribute to the clinical presentation of hospitalized patients in the psychiatric unit. Illicit drug use, in particular, has been associated with acute agitation, and questions can be raised as to what lasting effects drug use prior to admission may have throughout a patient's hospital stay...
October 6, 2016: Journal of Dual Diagnosis
Rodolfo Pérez-Garza, Gamaliel Victoria-Figueroa, Rosa Elena Ulloa-Flores
Background. Previous studies have reported sex differences in the clinical presentation and outcome of adult patients with schizophrenia; the aim of present study was to compare the clinical characteristics, social functioning, adherence to treatment, and cognition of adolescents with this diagnosis in a six-month followup. Methods. A total of 87 adolescents with a DSM-IV diagnosis of schizophrenia or schizophreniform disorder were evaluated with the Positive and Negative Symptoms Scale (PANSS), the Matrics Consensus Cognitive Battery (MCCB), Personal and Social Performance Scale (PSP), and the Rating of Medication Influences (ROMI)...
2016: Schizophrenia Research and Treatment
C Tessier, K Sweers, A Frajerman, H Bergaoui, F Ferreri, C Delva, N Lapidus, A Lamaziere, J P Roiser, M De Hert, P Nuss
Schizophrenia is a severe mental condition in which several lipid abnormalities-either structural or metabolic-have been described. We tested the hypothesis that an abnormality in membrane lipid composition may contribute to aberrant dopamine signaling, and thereby symptoms and cognitive impairment, in schizophrenia (SCZ) patients. Antipsychotic-medicated and clinically stable SCZ outpatients (n=74) were compared with matched healthy subjects (HC, n=40). A lipidomic analysis was performed in red blood cell (RBC) membranes examining the major phospholipid (PL) classes and their associated fatty acids (FAs)...
October 4, 2016: Translational Psychiatry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"